Drug intelligence / Profile preview

HXSS022

Development stage: Preclinical
Lead developer: Huaxia Shengsheng Pharmaceutical
Modality: Small Molecules

Overview

HXSS022 is a preclinical-stage small molecule candidate being developed by Huaxia Sangsheng Pharmaceutical for the treatment of Amyotrophic Lateral Sclerosis (ALS). The drug is part of the company's novel drug pipeline, which focuses on unmet clinical needs in neurological and other therapeutic areas. The research and development program is led by chief scientists from the Peking University School of Pharmacy. While specific details regarding its biological target or mechanism of action have not been publicly disclosed, it is categorized as a novel compound rather than a generic drug.

Beyond the preview

Go deeper on HXSS022.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HXSS022.

Explore the full profile